Rosiglitazone improves endothelial function and inflammation but not asymmetric dimethylarginine or oxidative stress inpatients with type 2 diabetes mellitus

Aaron S Kelly, Andrea M. Thelen, Daniel R. Kaiser, J. Michael Gonzalez-Campoy, Alan J. Bank

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

We compared the vascular effects of rosiglitazone versus glyburide and evaluated asymmetric dimethylarginine (ADMA) and oxidative stress as potential mechanisms associated with changes in vascular health in patients with type 2 diabetes mellitus (T2DM). Patients were randomized to 6 months of either rosiglitazone (n = 20) or glyburide (n = 16) in addition to metformin. The following variables were measured pre- and post-treatment: glucose, insulin, homeostasis model assessment (HOMA), hemoglobin A1c (HbA1c), C-peptide, blood pressure, lipids, C-reactive protein (CRP), ADMA, 8-isoprostane, oxidized LDL cholesterol, brachial artery flow-mediated dilation (FMD), endothelium-independent dilation (EID), and brachial and carotid artery stiffness. Rosiglitazone and glyburide treatment resulted in significant and equivalent decreases in glucose (p<0.0001) and HbA1c (p<0.0001), with a trend toward decreased HOMA (p=0.09). Rosiglitazone significantly decreased C-peptide (p < 0.01) with a strong trend toward decreased fasting insulin (p=0.05). Rosiglitazone reduced CRP compared with glyburide (p=0.001), but no differences were observed between groups for ADMA or the markers of oxidative stress. Rosiglitazone significantly improved FMD (p < 0.05) with trends toward improvements in carotid artery distension (p = 0.099) and distensibility (p = 0.078). In conclusion, compared with glyburide, rosiglitazone improves endothelial function and CRP in patients with T2DM. These improvements are not associated with reductions in ADMA or markers of oxidative stress.

Original languageEnglish (US)
Pages (from-to)311-318
Number of pages8
JournalVascular Medicine
Volume12
Issue number4
DOIs
StatePublished - Dec 1 2007

Fingerprint

rosiglitazone
Type 2 Diabetes Mellitus
Inpatients
Glyburide
Oxidative Stress
Inflammation
C-Reactive Protein
Dilatation
8-epi-prostaglandin F2alpha
Brachial Artery
C-Peptide
Carotid Arteries
Blood Vessels
Homeostasis
Hemoglobin C
Insulin
Glucose
Metformin
N,N-dimethylarginine
LDL Cholesterol

Keywords

  • Asymmetric dimethylarginine
  • Endothelial function
  • Oxidative stress
  • Rosiglitazone
  • Type 2 diabetes mellitus

Cite this

Rosiglitazone improves endothelial function and inflammation but not asymmetric dimethylarginine or oxidative stress inpatients with type 2 diabetes mellitus. / Kelly, Aaron S; Thelen, Andrea M.; Kaiser, Daniel R.; Gonzalez-Campoy, J. Michael; Bank, Alan J.

In: Vascular Medicine, Vol. 12, No. 4, 01.12.2007, p. 311-318.

Research output: Contribution to journalArticle

Kelly, Aaron S ; Thelen, Andrea M. ; Kaiser, Daniel R. ; Gonzalez-Campoy, J. Michael ; Bank, Alan J. / Rosiglitazone improves endothelial function and inflammation but not asymmetric dimethylarginine or oxidative stress inpatients with type 2 diabetes mellitus. In: Vascular Medicine. 2007 ; Vol. 12, No. 4. pp. 311-318.
@article{18ce6f3d8e7e4405a06b38b880cbcdf2,
title = "Rosiglitazone improves endothelial function and inflammation but not asymmetric dimethylarginine or oxidative stress inpatients with type 2 diabetes mellitus",
abstract = "We compared the vascular effects of rosiglitazone versus glyburide and evaluated asymmetric dimethylarginine (ADMA) and oxidative stress as potential mechanisms associated with changes in vascular health in patients with type 2 diabetes mellitus (T2DM). Patients were randomized to 6 months of either rosiglitazone (n = 20) or glyburide (n = 16) in addition to metformin. The following variables were measured pre- and post-treatment: glucose, insulin, homeostasis model assessment (HOMA), hemoglobin A1c (HbA1c), C-peptide, blood pressure, lipids, C-reactive protein (CRP), ADMA, 8-isoprostane, oxidized LDL cholesterol, brachial artery flow-mediated dilation (FMD), endothelium-independent dilation (EID), and brachial and carotid artery stiffness. Rosiglitazone and glyburide treatment resulted in significant and equivalent decreases in glucose (p<0.0001) and HbA1c (p<0.0001), with a trend toward decreased HOMA (p=0.09). Rosiglitazone significantly decreased C-peptide (p < 0.01) with a strong trend toward decreased fasting insulin (p=0.05). Rosiglitazone reduced CRP compared with glyburide (p=0.001), but no differences were observed between groups for ADMA or the markers of oxidative stress. Rosiglitazone significantly improved FMD (p < 0.05) with trends toward improvements in carotid artery distension (p = 0.099) and distensibility (p = 0.078). In conclusion, compared with glyburide, rosiglitazone improves endothelial function and CRP in patients with T2DM. These improvements are not associated with reductions in ADMA or markers of oxidative stress.",
keywords = "Asymmetric dimethylarginine, Endothelial function, Oxidative stress, Rosiglitazone, Type 2 diabetes mellitus",
author = "Kelly, {Aaron S} and Thelen, {Andrea M.} and Kaiser, {Daniel R.} and Gonzalez-Campoy, {J. Michael} and Bank, {Alan J.}",
year = "2007",
month = "12",
day = "1",
doi = "10.1177/1358863X07084200",
language = "English (US)",
volume = "12",
pages = "311--318",
journal = "Vascular Medicine (United Kingdom)",
issn = "1358-863X",
publisher = "SAGE Publications Ltd",
number = "4",

}

TY - JOUR

T1 - Rosiglitazone improves endothelial function and inflammation but not asymmetric dimethylarginine or oxidative stress inpatients with type 2 diabetes mellitus

AU - Kelly, Aaron S

AU - Thelen, Andrea M.

AU - Kaiser, Daniel R.

AU - Gonzalez-Campoy, J. Michael

AU - Bank, Alan J.

PY - 2007/12/1

Y1 - 2007/12/1

N2 - We compared the vascular effects of rosiglitazone versus glyburide and evaluated asymmetric dimethylarginine (ADMA) and oxidative stress as potential mechanisms associated with changes in vascular health in patients with type 2 diabetes mellitus (T2DM). Patients were randomized to 6 months of either rosiglitazone (n = 20) or glyburide (n = 16) in addition to metformin. The following variables were measured pre- and post-treatment: glucose, insulin, homeostasis model assessment (HOMA), hemoglobin A1c (HbA1c), C-peptide, blood pressure, lipids, C-reactive protein (CRP), ADMA, 8-isoprostane, oxidized LDL cholesterol, brachial artery flow-mediated dilation (FMD), endothelium-independent dilation (EID), and brachial and carotid artery stiffness. Rosiglitazone and glyburide treatment resulted in significant and equivalent decreases in glucose (p<0.0001) and HbA1c (p<0.0001), with a trend toward decreased HOMA (p=0.09). Rosiglitazone significantly decreased C-peptide (p < 0.01) with a strong trend toward decreased fasting insulin (p=0.05). Rosiglitazone reduced CRP compared with glyburide (p=0.001), but no differences were observed between groups for ADMA or the markers of oxidative stress. Rosiglitazone significantly improved FMD (p < 0.05) with trends toward improvements in carotid artery distension (p = 0.099) and distensibility (p = 0.078). In conclusion, compared with glyburide, rosiglitazone improves endothelial function and CRP in patients with T2DM. These improvements are not associated with reductions in ADMA or markers of oxidative stress.

AB - We compared the vascular effects of rosiglitazone versus glyburide and evaluated asymmetric dimethylarginine (ADMA) and oxidative stress as potential mechanisms associated with changes in vascular health in patients with type 2 diabetes mellitus (T2DM). Patients were randomized to 6 months of either rosiglitazone (n = 20) or glyburide (n = 16) in addition to metformin. The following variables were measured pre- and post-treatment: glucose, insulin, homeostasis model assessment (HOMA), hemoglobin A1c (HbA1c), C-peptide, blood pressure, lipids, C-reactive protein (CRP), ADMA, 8-isoprostane, oxidized LDL cholesterol, brachial artery flow-mediated dilation (FMD), endothelium-independent dilation (EID), and brachial and carotid artery stiffness. Rosiglitazone and glyburide treatment resulted in significant and equivalent decreases in glucose (p<0.0001) and HbA1c (p<0.0001), with a trend toward decreased HOMA (p=0.09). Rosiglitazone significantly decreased C-peptide (p < 0.01) with a strong trend toward decreased fasting insulin (p=0.05). Rosiglitazone reduced CRP compared with glyburide (p=0.001), but no differences were observed between groups for ADMA or the markers of oxidative stress. Rosiglitazone significantly improved FMD (p < 0.05) with trends toward improvements in carotid artery distension (p = 0.099) and distensibility (p = 0.078). In conclusion, compared with glyburide, rosiglitazone improves endothelial function and CRP in patients with T2DM. These improvements are not associated with reductions in ADMA or markers of oxidative stress.

KW - Asymmetric dimethylarginine

KW - Endothelial function

KW - Oxidative stress

KW - Rosiglitazone

KW - Type 2 diabetes mellitus

UR - http://www.scopus.com/inward/record.url?scp=38449122045&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38449122045&partnerID=8YFLogxK

U2 - 10.1177/1358863X07084200

DO - 10.1177/1358863X07084200

M3 - Article

C2 - 18048467

AN - SCOPUS:38449122045

VL - 12

SP - 311

EP - 318

JO - Vascular Medicine (United Kingdom)

JF - Vascular Medicine (United Kingdom)

SN - 1358-863X

IS - 4

ER -